Abacus Life Announces Closing of Public Offering of 11,500,000 Shares of Common Stock
Abacus Life has successfully closed its oversubscribed public offering, raising gross proceeds of $92 million by selling 11,500,000 shares of common stock at $8.00 per share. This includes the full exercise of the underwriters' option to purchase an additional 1,500,000 shares. The funds will support corporate operations, including buying life settlement policies, business strategies, working capital, and possibly repaying or refinancing debt. Piper Sandler, TD Securities, B. Riley Securities, and KKR Capital Markets acted as joint book-running managers. The offering's registration statement was declared effective by the SEC on June 20, 2024, and the final prospectus was filed on June 21, 2024.
This announcement does not constitute an offer to sell or a solicitation to buy these securities in any jurisdiction where such activities would be unlawful.
- Raised $92 million in gross proceeds from public offering.
- Successfully sold 11,500,000 shares, including the underwriters' option of 1,500,000 shares.
- None.
Abacus Life's public offering of 11,500,000 shares, priced at $8.00 per share, raises approximately
Life settlements are life insurance policies sold to third parties, often at a discount to face value, providing immediate liquidity to policyholders and potential high returns to investors. Abacus's strategy to use funds in this domain aligns with their core expertise in longevity and actuarial technology, potentially enhancing revenue streams.
Underwriting by reputable firms like Piper Sandler, TD Securities, B. Riley Securities and KKR Capital Markets underpins the credibility of this offering. These firms bring a level of due diligence and market understanding that can positively influence investor sentiment.
In the short term, investors might see fluctuations in stock price as the market absorbs the new shares. However, the long-term implications could be beneficial if Abacus effectively deploys the raised capital to generate higher returns through life settlements and other strategic initiatives.
In the context of the alternative asset management industry, Abacus's specialization in longevity and actuarial technology sets it apart. The successful closing of this public offering not only signals strong market confidence but also provides the company with substantial liquidity to capitalize on growth opportunities.
Market trends in the longevity risk management sector show increasing interest as investors seek diversified, non-correlated assets. Life settlements offer a unique investment opportunity, particularly attractive in a low-interest-rate environment where traditional fixed-income securities yield less.
Abacus's decision to allocate proceeds for general corporate purposes, including potential debt refinancing, could enhance its financial stability and credit profile. This strategic flexibility is important for navigating market uncertainties and seizing new opportunities as they arise.
For retail investors, understanding the niche market Abacus operates in is essential. The company's ability to leverage its expertise in actuarial technology to unlock value from life settlement policies could translate into strong performance, provided they manage associated risks effectively.
ORLANDO, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, today announced the closing of its oversubscribed underwritten public offering of 11,500,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares of common stock, at the public offering price of
Abacus intends to use net proceeds for its operations, including the purchase of life settlement policies, to support its overall business strategy, for working capital purposes and for general corporate purposes, which may include repayment and refinancing of its indebtedness.
Piper Sandler & Co., TD Securities (USA) LLC, B. Riley Securities and KKR Capital Markets LLC acted as joint book-running managers and representatives of the underwriters for the offering.
A registration statement on Form S-1 relating to this offering was declared effective by the Securities and Exchange Commission (“SEC”) on June 20, 2024. A final prospectus relating to and describing the terms of the offering was filed with the SEC on June 21, 2024 and may be obtained from: Piper Sandler & Co. by mail at 1251 Avenue of the Americas, 6th Floor, New York, NY 10020 or by email at prospectus@psc.com; TD Securities (USA) LLC by mail at 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846 or by email at TD.ECM_Prospectus@tdsecurities.com; B. Riley Securities by mail at 1300 17th Street North, Suite 1300, Arlington, VA 22209, by telephone at (703) 312-9580 or by email at prospectuses@brileyfin.com; or KKR Capital Markets LLC by mail at 30 Hudson Yards, 75th Floor, New York, NY 10001, Attention: Prospectus Delivery; or by accessing the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the shares of the Company’s common stock or any other securities, nor shall there be any sale of such shares of common stock or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Abacus Life, Inc.
Abacus is a leading vertically integrated alternative asset manager and market maker, specializing in longevity and actuarial technology. The Company is democratizing the life insurance space through three groundbreaking new channels: ABL Tech, ABL Wealth, and ABL Longevity Funds. Since 2004, Abacus has purchased life insurance policies from consumers seeking liquidity and has actively managed those policies over time (via trading, holding, and/or servicing). With over
Forward-Looking Statements
This communication may contain certain forward-looking statements within the meaning of the federal securities laws with respect to the offering. These forward-looking statements generally are identified by the words “believe,” “predict,” “project,” “propose,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “scales,” “representative of,” “valuation,” “potential,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negatives of these terms or variations of them. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are inherently subject to risks and uncertainties. These forward‐looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are beyond Abacus’ control, are difficult or impossible to predict and may differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that demand for Abacus’ life settlement and related offerings do not grow as expected, (ii) the ability of Abacus to retain existing customers and attract new customers, (iii) the potential inability of Abacus to manage growth effectively, (iv) the potential risks associated with Abacus’ revenue being concentrated in a limited number of customers, some of which are related parties, (v) the potential inability of Abacus to grow its market share of the life settlement industry or to achieve efficiencies regarding its operating model or other costs, (vi) negative trends in the life settlement industry impacting the value of life settlements, including increases to the premium costs of life insurance policies, increased longevity of insureds, and errors in the methodology and assumptions of life expectancy reports, (vii) legal challenges by insurers relating to the validity of the origination or assignment of certain life settlements, (viii) the enforceability of Abacus’ intellectual property rights, including its trademarks and trade secrets, and the potential infringement on the intellectual property rights of others, (ix) Abacus’ dependence on senior management and other key employees, and (x) the risk of downturns and a changing regulatory landscape in the industry in which Abacus operates. The foregoing list of factors is not exhaustive.
Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should carefully consider the foregoing factors and the other risks and uncertainties which will be more fully described in the documents filed by Abacus from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers of this communication are cautioned not to put undue reliance on forward-looking statements, and Abacus assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Abacus gives no assurance that it will achieve expectations.
Contacts:
Jeff Smith
Director of Marketing
1-800-561-4148 | jeff@abacuslife.com
Abacus Life Investor Relations
investors@abacuslife.com
Abacus Life Public Relations
press@abacuslife.com
FAQ
What was the outcome of Abacus Life's public offering on June 24, 2024?
How many shares were sold by Abacus Life in its recent public offering?
What will Abacus Life use the proceeds from the public offering for?
Which companies were the joint book-running managers for Abacus Life's public offering?
What was the offering price for Abacus Life's shares during the public offering?
